Drug Formulary Review Archives – May 1, 2006
May 1, 2006
View Issues
-
Pharmacist involvement may lower preventable ADEs rates after discharge
Pharmacist counseling and follow-up are associated with lower rates of preventable adverse drug events (ADEs) after patient discharge from the hospital, a new study indicates. -
FDA issues 2005 approvals for drugs, biologic products
The Center for Drug Evaluation and Research (CDER), the FDAs organization for setting and ensuring the standards for the safety and effectiveness of drugs and certain therapeutic biologic products, approved 78 new drug applications (NDAs) and two biologic license applications (BLAs) in 2005. -
Alert issued on tubing, catheter misconnections
The Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL, has issued a Sentinel Event Alert that asks health care organizations to pay special attention to how tubing and catheters are connected so dangerous misconnection errors can be prevented. -
News Briefs
Report: More pharmacists opting for part-time work; FDA extends review period for reintroduction of natalizumab; ACCU-CHEK Ultraflex Infusion Sets recalled; AHA issues statement regarding clopidogrel (Plavix) use -
New FDA Approvals
New indication for tacrolimus (Prograf) by Astellas Pharma US. The FDA has approved tacrolimus (Prograf), a drug that suppresses the bodys immune reaction, for the prevention of graft rejection in the recipients of heart transplants. -
In the Pipeline
Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections. -
Drug Criteria & Outcomes: Medications Used in Radiological Emergencies
Since Sept. 11, 2001, terror has become a common word in the American vocabulary. A recent addition are the words dirty bomb.